Forward looking statements

The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Trademarks

Except where otherwise noted, brand names designated by a ™ or © throughout this presentation are trademarks either owned by and/or licensed to CSL or its affiliates.
Reported Financials

Sales US$5,459 million, up 2% (up 7% @CC\(^1\))
EBIT US$1,758 million, up 7% (up 10% @CC)
- Adjusted for acquisition costs\(^2\) up 12% @CC
NPAT US$1,379 million, up 6% (up 8% @CC)
- Adjusted for acquisition costs up 10% @CC
R&D investment US$463 million
EPS US$2.92, up 8% (up 11% @CC)
- Adjusted for acquisition costs up 13% @CC
Final dividend increased to US$0.66, unfranked (up 10%)
- Converted to AUD ~$0.90, up 39%

---

1. Constant Currency (CC) removes the impact of exchange rate movements to facilitate comparability.
2. One off costs connected with the acquisition of the Novartis influenza business
Highlights

- Acquisition of Novartis global influenza vaccines business
- bioCSL business turnaround
- Hizentra® - EMA & U.S. FDA approve flexible dosing
- CSL 654 (rIX-FP) – license application submitted in U.S. & EU
- CSL 627 (rFVIII-SC) – license application submitted in U.S.
- CSL 112 (rHDL) – global phase IIb trial recruiting rapidly
- A$950 million share buyback completed
- New A$1 billion buyback* announced
- New CHF400 million & USD100 million US private placement

* CSL reserves the right to suspend or terminate buybacks at any time
Facilities Expansion
Investing for Growth

Recombinant
• Broke ground on rCOAG plant in Lengnau, Switzerland

Plasma
• Completed validation runs for the new Privigen® facility in BMW
• Construction underway for new albumin facility in BMW
• Obtained FDA and other regulatory approvals for the new base fractionation and albumin facility in Kankakee
• Broke ground on a new packaging facility in Marburg, Germany
• Started project to expand Berinert® production capacity

Collections
• 21 centres opened in the USA, plus 1 in Hungary, increasing the fleet in the US to 119 centres, or 128 centres globally
Group Revenue FY15 US$5.6b

Product Groupings

- IVIG 29%
- SCIG 9%
- Hyper IG 3%
- rFVIII 8%
- pd Coag 10%
- Albumin 14%
- Peri-op 8%
- Other 8%
- Specialty Products 16%
- Pharma & Vaccines 8%

IPL 3%
Broad Sales Reach

North America 41%
Europe 28%
Asia 10%
ROW 13%
bioCSL 8%

FY15 US$5.5b
CSL Behring
Product Sales up 7% @ CC

Sales for the 12 month period

Jun 14
US$4,926m

Jun 15
US$5,029m

- Immunoglobulins
- Albumin
- pdCoag
- Helixate®

Specialty Products
Immunoglobulins
Sales up 5% @CC

Sales for the 12 month period

US$2,320m
US$2,326m

Highlights

Normal IG volume up 8%

IVIG
- Europe
  - CIDP indication driving strong Privigen® demand
- North America
  - Competitive pressure
  - 340B utilisation

SCIG
- Ongoing strong demand for Hizentra® in North American and European markets
- Flexible dosing option and home care convenience underpinning demand
Albumin
Sales up 12% @ CC

Highlights

China
- Ongoing strong demand
- Improving penetration into Tier 2 & Tier 3 cities

US
- Solid demand continues
- Initiatives focusing on IDNs and large hospitals

Sales for the 12 month period

US$M

Jun 14
US$694m

Jun 15
US$754m
Haemophilia
Sales up 3% @ CC

Highlights

PdFVIII
- Growth in Beriate® – Brazil, Poland and Germany
- Solid performance from Haemate® / Humate®
- Ongoing transition to recombinant therapies

Helixate®
- Positive results with US patient retention program
- New entrants

Sales for the 12 month period

Jun 14
US$1,064m

Jun 15
US$1,026m

pdCoag

Helixate®
Specialty Products
Sales up 15% @CC

Highlights

Kcentra®
• Ongoing strong demand in the U.S.

Berinert® P
• Self administration label driving new patient take-up.

Zemaira®
• New patient acquisition
• Launch of diagnostic testing program driving patient identification

Sales for the 12 month period
Highlights

Business turnaround initiatives driving a return to growth

Influenza sales A$145m
- Up 18% @CC
- Increased U.S. sales following the re-establishment of in-house commercial operations
- First to market in U.S., U.K. and Germany

QIV development
Zostavax* listed on Aust. NIP
Rapivab* commercialisation rights

---

1 Shown in Australian dollars to highlight operational performance
* Zostavax is a trademark of Merck & Co. Inc.
Rapivab is a trademark of BioCryst Pharmaceuticals Inc..
rIX-FP
- rIX-FP Phase III efficacy data supports 7-14 day dosing
- BLA accepted for review by FDA in February
- MAA review procedure commenced by EMA in March

rVIII-SingleChain
- Phase I/III data supports twice weekly dosing
- BLA accepted for review by FDA in July

rVIIa-FP
- Congenital deficiency Phase I/II commenced
- Phase II/III in patients with inhibitors commenced

Hizentra®
- Hizentra® flexible dosing registration in EU and US
- Hizentra® CIDP orphan drug designation in US
Beriplex®
- Commencement of Beriplex® Japan Phase III study

Berinert®
- Pivotal Phase III subcutaneous prophylaxis study recruiting well

Zemaira®/Respreeza® (Alpha1-Proteinase Inhibitor)
- Patients with AATD treated with Respreeza® have lower annual rate of lung density decline
- EMA CHMP recommended granting marketing authorisation for Respreeza® to treat patients with AATD in June

CSL112 (reconstituted High Density Lipoprotein)
- Phase IIa data supports mechanism of action & further development
- Commencement of AEGIS-I Phase IIb study
- Recruiting rapidly
• Acquisition of Novartis global influenza vaccines business (NVS-IV) completed 31 July 2015
• Seqirus™ becomes the second largest influenza vaccine company globally
  • Combined influenza vaccine sales expected to approach US$1 billion in 3 to 5 years
  • Manufacturing plants in US, UK, Germany & Australia
  • Diversified product portfolio
• Significant value creation potential for CSL
Outlook\textsuperscript{1} for FY16

“CSL Guidance Reaffirmed”

\begin{tabular}{|l|l|}
\hline
\textbf{CSL\textsuperscript{2}} & \\
\hline
Revenue growth & \textasciitilde7\% @CC\textsuperscript{4} \\
NPAT growth & \textasciitilde5\% @CC\textsuperscript{4} \\
\hline
\textbf{NVS-IV\textsuperscript{3}} (11 Months) & \\
\hline
Revenue & \textasciitildeUS\$450m\textsuperscript{5} \\
NPAT & \textasciitildeBreakeven \\
\hline
\end{tabular}

- New share buyback A\$1 billion\textsuperscript{6}
- EPS growth will exceed NPAT growth driven by past and current capital management initiatives
- NVS-IV gain on acquisition less integration costs \textasciitildeUS\$130 million

1 For forward looking statements, refer to Legal Notice on page 2
2 Excludes Novartis influenza vaccines business (NVS-IV)
3 Influenza vaccine business acquired from Novartis 31 July 2015
4 Constant Currency (CC) removes the impact of exchange rates movements to facilitate comparability
5 Excludes gain on acquisition \textasciitildeUS\$200m
6 CSL reserves the right to suspend or terminate buybacks at any time
Business Growth

Core Products
Recombinant Coagulation Factors
- rIX-FP, rVIII-SC, rVIIa-FP, rVWF

CSL112
New treatment paradigm in ACS
High margin contributor

Biotech
mAbs in core therapeutic segments

Recombinant Coagulation Factors
- rIX-FP, rVIII-SC, rVIIa-FP, rVWF

Specialty Products
Multiple high margin contributors: RiaSTAP®, Kcentra®, CytoGam®, Berinert®, Zemaira®

Core Products
Relentless Commitment to lowest cost base;
Operational and Financial Strength and Efficiency.
Continued Ig and Albumin growth through innovation and market expansion

18
# Financial Appendix¹

<table>
<thead>
<tr>
<th></th>
<th>CSL²</th>
<th>NVS-IV³ (11 months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Year ended June US$ Millions</td>
<td>FY15 Actual</td>
<td>FY16 Guidance</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>5,613</td>
<td>~7% @CC⁴</td>
</tr>
<tr>
<td><strong>Reported Net Profit after Tax</strong></td>
<td>1,379</td>
<td>~Breakeven</td>
</tr>
<tr>
<td>NVS-IV gain on acquisition less integration costs⁶</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted Net Profit after Tax</strong></td>
<td>1,401</td>
<td>~5% @CC⁴</td>
</tr>
<tr>
<td><strong>FX Impact⁷</strong></td>
<td>~(70)</td>
<td></td>
</tr>
</tbody>
</table>

---

¹ For forward looking statements, refer to Legal Notice on page 2
² Excludes Novartis influenza vaccines business (NVS-IV)
³ Influenza vaccine business acquired from Novartis 31 July 2015
⁴ Constant Currency (CC) removes the impact of exchange rates movements to facilitate comparability
⁵ Excludes gain on acquisition ~US$200m
⁶ Gain on acquisition ~US$200m and integration costs (~US$70m) are included in reported NPAT
⁷ Assumes current rates remain steady for the remainder of the year, giving rise to the unfavourable full year FX impact